Company Description
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.
Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.
NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Country | United States |
IPO Date | May 28, 2015 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 10 |
CEO | Brian M. Murphy |
Contact Details
Address: 525 Executive Boulevard Elmsford, New York United States | |
Website | https://www.nanovibronix.com |
Stock Details
Ticker Symbol | NAOV |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001326706 |
CUSIP Number | 63008J108 |
ISIN Number | US63008J6038 |
Employer ID | 00-0000000 |
SIC Code | 3842 |
Key Executives
Name | Position |
---|---|
Brian M. Murphy | Chief Executive Officer & Director |
Stephen R. Brown CPA | Chief Financial Officer |
Amir Rippel | Vice President of Marketing |
Dr. Harold Jacob M.D. | Chief Medical Officer & Director |
Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 11, 2024 | 8-K | Current Report |
Nov 22, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | 10-Q | Quarterly Report |
Oct 29, 2024 | ARS | Filing |
Oct 29, 2024 | DEFA14A | Filing |
Oct 29, 2024 | DEF 14A | Filing |
Oct 11, 2024 | 8-K | Current Report |
Oct 07, 2024 | 8-K | Current Report |
Sep 25, 2024 | 8-K | Current Report |